Description
Anti-LAG-3 Antibody, ADCC Enchanced (BioBet-CB-018LX) is a glycosylation-modified anti-LAG-3 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced LAG-3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
LAG3
Full Name
lymphocyte-activation gene 3
Background
Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4.
Alternative Names
LAG3; lymphocyte-activation gene 3; CD223; lymphocyte activation gene 3 protein
Gene ID
3902
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4
Antibody Clone
BioBet-CB-018LX
Description
ADCC-Enhanced Anti-Human LAG-3 (Relatlimab) Antibody is derived from clone Relatlimab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the LAG-3, and it is intended for the research of Melanoma.
Antibody Indication
Melanoma
